Mitotane
Top View
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
- A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101), a BH3 Mimetic, in Patients with Advanced Adrenal Cortical Carcinoma
- High-Dose Mitotane Strategy in Adrenocortical Carcinoma
- Pharmacological Profile and Effects of Mitotane In
- Network Chemotherapy Protocols
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Subacute Cutaneous Lupus Erythematosus Induced by Mitotane
- LCA Oral SACT Counselling Handbook
- Temozolomide Therapy: Focus on Patients with Pituitary Carcinoma
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- MANUAL for Medical Facilities
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- Longitudinal Trends in Use and Costs of Targeted Therapies for Common Cancers in Taiwan: a Retrospective Observational Study
- Etoposide, Doxorubicin and Cisplatin Plus Mitotane in the Treatment of Advanced Adrenocortical Carcinoma: a Large Prospective Phase II Trial
- Drug Interactions Adjuvant Therapy for Breast Cancer Using UBRAJCAF ; Cyclophosphamide, Doxorubicin and Updated in Precautions Fluorouracil
- Phase II Study of Weekly Paclitaxel and Sorafenib As Second/Third-Line
- Advanced Adrenocortical Carcinoma –
- Adult Antiemetic Management of Chemotherapy-Induced Nausea